Francisco Silva Biography and Net Worth



Secretary, Director & VP-Research & Development

What is Francisco Silva's net worth?

The estimated net worth of Francisco Silva is at least $204,347.83 as of April 8th, 2024. Mr. Silva owns 149,159 shares of BioRestorative Therapies stock worth more than $204,348 as of April 20th. This net worth approximation does not reflect any other assets that Mr. Silva may own. Additionally, Mr. Silva receives a salary of $375,000.00 as VP at BioRestorative Therapies. Learn More about Francisco Silva's net worth.

How old is Francisco Silva?

Mr. Silva is currently 49 years old. There are 3 older executives and no younger executives at BioRestorative Therapies. The oldest executive at BioRestorative Therapies is Mr. Robert Eugene Kristal, Chief Financial Officer, who is 56 years old. Learn More on Francisco Silva's age.

What is Francisco Silva's salary?

As the VP of BioRestorative Therapies, Inc., Mr. Silva earns $375,000.00 per year. The highest earning executive at BioRestorative Therapies is Mr. Lance Alstodt, Chairman of the Board, President & CEO, who commands a salary of $400,000.00 per year. Learn More on Francisco Silva's salary.

How do I contact Francisco Silva?

The corporate mailing address for Mr. Silva and other BioRestorative Therapies executives is 40 MARCUS DRIVE, MELVILLE NY, 11747. BioRestorative Therapies can also be reached via phone at (631) 760-8100 and via email at [email protected]. Learn More on Francisco Silva's contact information.

Has Francisco Silva been buying or selling shares of BioRestorative Therapies?

Francisco Silva has not been actively trading shares of BioRestorative Therapies during the past quarter. Most recently, on Friday, March 31st, Francisco Silva bought 747 shares of BioRestorative Therapies stock. The stock was acquired at an average cost of $3.56 per share, with a total value of $2,659.32. Following the completion of the transaction, the vice president now directly owns 159,690 shares of the company's stock, valued at $568,496.40. Learn More on Francisco Silva's trading history.

Who are BioRestorative Therapies' active insiders?

BioRestorative Therapies' insider roster includes Lance Alstodt (CEO), and Francisco Silva (VP). Learn More on BioRestorative Therapies' active insiders.

Are insiders buying or selling shares of BioRestorative Therapies?

During the last year, BioRestorative Therapies insiders bought shares 2 times. They purchased a total of 5,200 shares worth more than $13,048.00. The most recent insider tranaction occured on July, 27th when Major Shareholder Dale Broadrick bought 1,000 shares worth more than $2,800.00. Insiders at BioRestorative Therapies own 21.6% of the company. Learn More about insider trades at BioRestorative Therapies.

Information on this page was last updated on 7/27/2023.

Francisco Silva Insider Trading History at BioRestorative Therapies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/31/2023Buy747$3.56$2,659.32159,690View SEC Filing Icon  
11/21/2022Buy943$2.62$2,470.66166,046View SEC Filing Icon  
10/11/2022Buy806$3.69$2,974.14164,378View SEC Filing Icon  
8/29/2022Buy2,816$3.21$9,039.36163,572View SEC Filing Icon  
8/26/2022Buy2,600$3.35$8,710.00160,756View SEC Filing Icon  
11/19/2021Buy4,000$6.66$26,640.00View SEC Filing Icon  
9/4/2019Buy20,955$0.24$5,029.20
8/30/2019Buy18,000$0.28$5,040.0019,503View SEC Filing Icon  
8/26/2019Buy7,500$0.27$2,025.00View SEC Filing Icon  
8/22/2019Buy17,374$0.26$4,517.24View SEC Filing Icon  
See Full Table

Francisco Silva Buying and Selling Activity at BioRestorative Therapies

This chart shows Francisco Silva's buying and selling at BioRestorative Therapies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioRestorative Therapies Company Overview

BioRestorative Therapies logo
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Read More

Today's Range

Now: $1.37
Low: $1.33
High: $1.45

50 Day Range

MA: $1.36
Low: $1.28
High: $1.50

2 Week Range

Now: $1.37
Low: $1.20
High: $7.13

Volume

162,028 shs

Average Volume

552,872 shs

Market Capitalization

$9.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

61.51